ZBTB7A

Across TCGA pan-cancer cohorts, ZBTB7A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZBTB7A data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZBTB7A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBTB7A expression acts as an unfavorable survival marker.

PDAC and CCRCC are the cancer types where ZBTB7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.250	0.934	.024	8	view →
CCRCC	DFS	Median	All	0.704	1.000	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ZBTB7A–PDAC (DFS)

Open the PDAC breakdown →